The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study

The impact of tube replacement timing during LCIG therapy on PEG-J associated adverse events: a retrospective multicenter observational study

Abstract Background Levodopa–carbidopa intestinal gel (LCIG) treatment, a unique drug delivery system for patients with advanced Parkinson’s disease (PD), is covered by health insurance in Japan since September 2016. Various LCIG procedure/device-associated adverse events (AEs) have been reported; h...

Full description

Bibliographic Details
Main Authors: Kanefumi Yamashita, Yukinori Yube, Yukinao Yamazaki, Takehide Fukuchi, Masaki Kato, Tomoyuki Koike, Takeshi Uehara, Yoshiou Ikeda, Satoshi Furune, Hidehiro Murakami, Eiji Kubota, Shinsuke Fujioka, Yoshinori Sato, Xiaoyi Jin, Tomohiko Suzuki, Kazuhiro Furukawa, Yoshio Tsuboi
Format: Article
Language:English
Published: BMC 2021-06-01
Series:BMC Neurology
Subjects:
Levodopa–carbidopa intestinal gel
Parkinson’s disease
Percutaneous endoscopic gastrojejunostomy
Online Access:https://doi.org/10.1186/s12883-021-02269-7

Internet

https://doi.org/10.1186/s12883-021-02269-7

Similar Items